Navigation Links
Valensa International and Parry Nutraceuticals Join Forces in the Global Natural Products Marketplace
Date:11/26/2008

ORLANDO, Fla., Nov. 26 /PRNewswire/ -- Valensa International (Orlando, USA) and Parry Nutraceuticals (Division of E.I.D. Parry (India) Ltd., Chennai, India), as part of a growth strategy for both companies, have joined forces to usher in the next generation of high-performance nutritional products from plant-derived sources for the condition-specific dietary supplement, functional food and fortified beverage sectors. EID Parry acquired a 48% strategic stake in U.S. Nutraceuticals doing business as Valensa International. Valensa's "Direct to Marketers" product development and business strategy will be expanded under a new management team led by Valensa's President, Dr. Rudi E. Moerck, which includes executives from both companies. With the Valensa investment, Parry becomes a marketing partner and a strategic source of botanical materials and technology for new and existing Valensa products in the fast-growing areas of Omega-3 Essential Fatty Acids (ALA, EPA and DHA); phycocyanins and carotenoids including astaxanthin, lycopene, lutein, zeaxanthin; and others. The new arrangement will strengthen Valensa's ability to market its science-based products globally. Current areas of co-marketing between the companies include astaxanthin and Valensa's patented SpiruZan(TM), a Spirulina/Astaxanthin product co-launched by the two companies at Natural Products Expo East in Boston and HI Europe in Paris.

According to Dr. Rudi E. Moerck, the companies have the same philosophies on sustainable natural product production and focus on natural ingredients made using environmentally responsible technology such as Valensa's organic-certified supercritical carbon dioxide extraction plant in Florida, USA. "Parry Nutraceuticals shares Valensa International's commitment to creating the highest-quality products based on the best available science for the condition-specific human health and nutrition market," he said. "Parry Nutraceuticals is one of the leading producers of ultra-high-quality raw materials including organic Spirulina and carotenoids like beta carotene, astaxanthin, lutein and tomato lycopene. Our cooperative new product development work with Parry will allow us to accelerate our new product development efforts to deliver some of the most exciting new products to the market," he added.

Two Leaders Working Together

Valensa and Parry recently introduced a new dietary supplement, SpiruZan(TM) -- a synergistic complex of micro-algae-based organic Spirulina and Astaxanthin in a small, easy-to-swallow 500 mg caplet presentation. SpiruZan combines the well-known nutritional properties of organic Spirulina with the superior antioxidant properties of Astaxanthin to deliver a "brain+body" supplement that offers enhanced protection from both dietary and environmental stress factors. SpiruZan is now available, providing 1 mg astaxanthin in an organic Spirulina serving. Spirulina product line extensions are also planned.

Parry Nutraceuticals produces the only GRAS-certified Spirulina that is also certified under USDA NOP, OCIA-IFOAM, Naturland and ECOCERT organic standards. Valensa's ingredients are manufactured using the company's DeepExtract(TM) High Pressure Supercritical CO2 Extraction and O2B(TM) Peroxidation Blocker technology, yielding more of the micronutrients contained in natural botanical materials and protecting both products and people from the problems associated with oxidation and rancidification.

    For further information, contact:

    Dr. Rudi E. Moerck, President
    Voice: 210-632-0695
    Fax: 352-483-2095

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Valensa International
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Valensa and Parry Nutraceuticals Introduce Organic SpiruZan(TM) Spirulina/Astaxanthin Complex as Lifestyle Support for a Fast-Paced World
2. International Formula Council Statement on Melamine and Infant Formulas
3. Pulmonary Hypertension Treated with Stem Cells : International Medical Team Announces Patient Results in Adult Stem Cell Clinical Study for Pulmonary Hypertension
4. MINRAD International, Inc. Announces Termination of RxElite Holdings Inc. as Anesthetics Distributor for the Human Market in United States
5. Lights Out For Bed Bugs as "BEST YET" Cedar Oil Solution Solves International Bed Bug Dilemma
6. AirMed International wins Air Ambulance of the Year for Second Consecutive Year
7. Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc.
8. Permanent International Healthcare Marketplace and Education Center Set to Open in New York City in 2013
9. Epocrates Offers International Market Research Panel
10. Accreditation to the International Standards Organization for Quality Management Granted to First U.S. Lab
11. MINRAD International, Inc. to Discuss Current Business Conditions on Tuesday, November 25, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... FL (PRWEB) , ... February 13, 2016 , ... The ... environmental impact of American businesses. , The increasingly modern world of instantaneous consumption ... often on non-renewable energy sources such as oil and coal, which pollutes our air, ...
(Date:2/13/2016)... ... 2016 , ... When an Au Pair comes all the way around the world ... for and they are often worried things won’t go well. More often than not, however, ... Au Pair of the Year winner’s all commented how their Au Pairs have become a ...
(Date:2/12/2016)... ... February 12, 2016 , ... According to an article published February ... a significant portion of hernia repairs throughout the United States. Commenting on this article, ... notes that this trend has not only been expected, but it seems to be ...
(Date:2/12/2016)... Seattle, WA, and Washington, DC (PRWEB) , ... ... ... PATH and the Siemens Foundation today announced a new initiative—the Siemens ... technologies for low-resource settings. The partnership will recruit top students from U.S. ...
(Date:2/12/2016)... VA (PRWEB) , ... February 12, 2016 , ... ... Feb. 29, 2016 — 1:30 p.m. – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination ... in the life cycle of pharmaceutical products, garnering increased attention from all stakeholders ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Feb. 12, 2016  This month,s issue of the ... takes an in-depth look at various causes and ... prescription drug spending, which has generated significant public outrage ... Editor-in-Chief Laura E. Happe , PharmD, MPH. ... , PharmD, MPH. --> In 2014 prescription ...
(Date:2/12/2016)... MONTREAL , February 12, 2016 ... sofern nicht anders vermerkt)   ... Unternehmens http://www.telestatherapeutics.com abrufbar.    ... Website des Unternehmens http://www.telestatherapeutics.com ... Inc. (TSX:TST; PNK:BNHLF) veröffentlichte heute seinen Konzernabschluss ...
(Date:2/12/2016)... Feb. 12, 2016  Sequent Medical, Inc. announced today ... to evaluate the safety and effectiveness of the WEB™ ... ruptured intracranial aneurysms.  Prof Laurent Spelle , MD, ... Paris, France and Principal Investigator of ... France and Germany.  Although patients with ...
Breaking Medicine Technology: